Shree Ganesh Remedies is currently trading at Rs. 830.90, up by 89.50 points or 12.07% from its previous closing of Rs. 741.40 on the BSE.
The scrip opened at Rs. 889.65 and has touched a high and low of Rs. 889.65 and Rs. 772.60 respectively. So far 52834 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 950.05 on 26-Jul-2024 and a 52 week low of Rs. 557.95 on 15-May-2024.
Last one week high and low of the scrip stood at Rs. 889.65 and Rs. 621.10 respectively. The current market cap of the company is Rs. 1060.39 crore.
The promoters holding in the company stood at 72.80%, while Institutions and Non-Institutions held 0.01% and 27.19% respectively.
Shree Ganesh Remedies (SGRL) has executed long-term Strategic Supply Agreement (SSA) with one of the foremost players in the Japanese market. The agreement, formalised on January 30, 2025, is set for an initial term of three years, with the potential for extension by an additional two years.
Under this strategic partnership, SGRL will engage in contract manufacturing for a total of three innovative products, which are poised to make their debut as the first of their kind in India. These products will be developed employing advanced methodologies in Chlorination and Reduction chemistry.
Shree Ganesh Remedies is engaged in manufacturing and dispatch of drug intermediates and chemicals like amine hydrochloride and specialty fine chemicals for pharmaceutical industry.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: